TDOC:NYSETeladoc Health, Inc. Analysis

Teladoc Health (TDOC) is trading at $6.48, comfortably above its 20‑day SMA (5.74) and 50‑day SMA (5.45) but still below the 200‑day SMA (6.87), indicating short‑term momentum within a longer‑term downtrend. The RSI sits at 69.6, flirting with overbought levels, while the MACD remains bullish (line > signal) and volume is increasing, suggesting some upward pressure toward the nearby resistance at $6.76. However, the stock is highly volatile (30‑day volatility ≈ 51%) and carries a beta of 1.95, exposing it to amplified market swings. The market sentiment is extremely optimistic, reflected by a Fear & Greed Index of 88.21 (Extreme Greed).
Fundamentally, TDOC posted a modest 2% revenue decline to $613.8 M and continues to generate negative margins (gross ≈ 69%, operating ≈ ‑8%). Losses remain sizable (trailing EPS ‑29.1, forward EPS ‑0.68) and debt ($1.04 B) is high relative to equity (D/E ≈ 78%). Yet the DCF‑derived fair value of $13.79 implies more than 100% upside, while the price‑to‑book (0.83) and price‑to‑sales (0.46) ratios suggest the stock is cheap on a balance‑sheet basis. Activist Pineal Capital’s push for a share‑repurchase program adds a potential catalyst, but the company must improve cash conversion and profitability to justify the valuation.